Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.3441 USD
−7.68 M USD
4.60 M USD
3.29 M
About InMed Pharmaceuticals Inc.
Sector
CEO
Eric A. Adams
Headquarters
Vancouver
Website
Founded
1981
FIGI
BBG000BT4589
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the research and development of small molecule pharmaceuticals drug candidates. The BayMedica segment focuses on the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
INM | This is a Runner | LONGInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment
Looks like a great buying opportunity Looks like a great buying opportunity, the stock looks highly oversold, with a short term spike in volatility, this could be a good candidates for a mind to long term bull run and considering the new report on the benefits of cannabinoids.
Huge Gap on InMed. INMInMed Pharmaceuticals produced an absolutely monster gap that now needs to be worked backwards in these very bearish circumstances. Fibs give some initial goals. Negative momentum loop done. The pull out will on a divergence or completion of Fibgoals, whichever occurs first.
InMed needs medicine. INMGoals 0.56, 0.49. Invalidation at 0.89.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere
INM 1W Swing editiontest
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research and development of novel. It also involves in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazza
INM $7.5 target short termFirst has to maintain the .236 fib at $4.71 for me to consider an entry, getting to $7.5+ shouldn't be a problem after that.
big breakout if resistance breaks. be patient hererecently rejected at resistance, but if it breaks we know what will happen... a test of 7 and 50 percent run that day! just like pola did with it broke top trendline resistance friday! we just missed that one :( next time! good luck longs ! have a great marthin luther king jr day tomorrow <3
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of INM is 0.2359 USD — it has increased by 4.07% in the past 24 hours. Watch InMed Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange InMed Pharmaceuticals Inc. stocks are traded under the ticker INM.
INM stock has fallen by −19.40% compared to the previous week, the month change is a 8.14% rise, over the last year InMed Pharmaceuticals Inc. has showed a −43.70% decrease.
INM stock is 6.85% volatile and has beta coefficient of 3.59. Track InMed Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is InMed Pharmaceuticals Inc. there?
Today InMed Pharmaceuticals Inc. has the market capitalization of 782.79 K, it has increased by 1.03% over the last week.
Yes, you can track InMed Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
InMed Pharmaceuticals Inc. is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
INM net income for the last quarter is −1.94 M USD, while the quarter before that showed −1.72 M USD of net income which accounts for −12.47% change. Track more InMed Pharmaceuticals Inc. financial stats to get the full picture.
No, INM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 13.00 employees. See our rating of the largest employees — is InMed Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. InMed Pharmaceuticals Inc. EBITDA is −7.80 M USD, and current EBITDA margin is −163.77%. See more stats in InMed Pharmaceuticals Inc. financial statements.
Like other stocks, INM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade InMed Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So InMed Pharmaceuticals Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating InMed Pharmaceuticals Inc. stock shows the sell signal. See more of InMed Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.